TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19811696

Group type: EXPERIMENTAL
Intervention: Dietary intake of lignans (mean intake 1224 mug/d, sd 539)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dietary intake of lignans
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intake of rye products, berries, coffee, tea and roots
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intake of rye products and coffee
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intake of water-insoluble fibre
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intake of vegetables and rye products
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intake of water-soluble fibre
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intake of lariciresinol
Number of subjects: 100
Study: 17617528

Group type: EXPERIMENTAL
Intervention: Topotecan plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various doublets, triplets, and quartlets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent cisplatin
Number of subjects: 0
Study: 16247428

Group type: EXPERIMENTAL
Intervention: Continuous intravenous (c.i.v.) administration of rhG-CSF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) administration of rhG-CSF
Number of subjects: 30
Study: 12385079

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy group (PPG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cognitive behavior group (CBG)
Number of subjects: 27
Study: 8283893

Group type: EXPERIMENTAL
Intervention: Allopurinol pretreatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3281489

Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg over 3 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (single dose: 500 mg sulfadoxine and 25 mg pyrimethamine)
Number of subjects: 98
Study: 31181957

Group type: EXPERIMENTAL
Intervention: Best Practice Alert (BPA)
Number of subjects: 1906

Group type: COMPARATOR
Intervention: No Best Practice Alert (no BPA)
Number of subjects: 1906
Study: 29319062

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Xylitol (XYL)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chlorhexidine + Xylitol (CHX+XYL)
Number of subjects: 75
Study: 24774992

Group type: EXPERIMENTAL
Intervention: Preconditioned group (PCG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 16
Study: 23855725

Group type: COMPARATOR
Intervention: FIFA 11+ warm-up
Number of subjects: 20
Study: 21645890

Group type: EXPERIMENTAL
Intervention: 2‐ to 3‐hour group
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 4‐ to 5‐hour group
Number of subjects: 432

Group type: COMPARATOR
Intervention: 0‐ to 1‐hour group
Number of subjects: 432

Group type: COMPARATOR
Intervention: 8‐ to 9‐hour group
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 2‐ to 3‐hour and 4‐ to 5‐hour groups
Number of subjects: 432
Study: 19826283

Group type: EXPERIMENTAL
Intervention: Blood flow restriction during low-intensity dynamic knee extension exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nonoccluded leg during low-intensity dynamic knee extension exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both conditions (blood flow restriction and nonoccluded)
Number of subjects: 11
Study: 16717297

Group type: EXPERIMENTAL
Intervention: Prostacyclin (10 microg, Flolan)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonpulsatile CPB flow rates (2.4 L/min/m2 to either 1.8 or 3.0 L/min/m2)
Number of subjects: 10
Study: 15058375

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) combined with surgical treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Surgical treatment alone (control group)
Number of subjects: 24
Study: 11568950

Group type: EXPERIMENTAL
Intervention: Graphical method based on Cook and Weisberg's marginal model plot
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized additive model (GAM)
Number of subjects: 0
Study: 9455714

Group type: EXPERIMENTAL
Intervention: Ranitidine 2 mg/kg with Metoclopramide 0.2 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ranitidine 2 mg/kg with Domperidone 0.3 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Famotidine 0.5 mg/kg with Metoclopramide 0.2 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Famotidine 0.5 mg/kg with Domperidone 0.3 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7956571

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 42
Study: 2731781

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1103722

Group type: EXPERIMENTAL
Intervention: Gentamicin (1 mg/kg, 1-hour intravenous infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sisomicin (1 mg/kg, 1-hour intravenous infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg, 1-hour intravenous infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All antibiotics tested
Number of subjects: 12
Study: 31273773

Group type: EXPERIMENTAL
Intervention: Pectoral nerves-2 (PECS-2) block
Number of subjects: 50

Group type: COMPARATOR
Intervention: No block
Number of subjects: 50
Study: 27916398

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg twice daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Best available therapy (hydroxyurea, interferon, pegylated interferon, pipobroman, anagrelide, approved immunomodulators, or no cytoreductive treatment)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 149

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 149
Study: 26006222

Group type: EXPERIMENTAL
Intervention: Dex/Bup/Fen group (1 mL epidural dexmedetomidine 0.5 µg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bup/Fen group (intrathecal hyperbaric bupivacaine 5 mg and epidural mixture of 10 mL plain bupivacaine 0.25 % and fentanyl 50 μg)
Number of subjects: 80
Study: 22674972

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit® balance exercise programme (12 supervised 30-min sessions, twice a week for 6-7 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 84
Study: 21849373

Group type: EXPERIMENTAL
Intervention: Supervised training group with verbal instruction from a physiotherapist
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unsupervised training group after supervised demonstration session
Number of subjects: 18
Study: 18707821

Group type: EXPERIMENTAL
Intervention: 3 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 8 months of neoadjuvant hormonal therapy (flutamide and goserelin) before 66 Gy radiotherapy
Number of subjects: 378
Study: 17594758

Group type: COMPARATOR
Intervention: Zonisamide
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Post-marketing surveillance
Number of subjects: 848
Study: 15625041

Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Conventional treatment (medical counseling on diet and health without drug treatment)
Number of subjects: 1000
Study: 11595000

Group type: EXPERIMENTAL
Intervention: PNU-142633 (50 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9558049

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8061848

Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spirapril 24 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3197697

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oxcarbazepine
Number of subjects: 25
Study: 31869474

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Exercise (AIEX)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Concurrent Exercise (CEX)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (REX)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 44
Study: 30304326

Group type: EXPERIMENTAL
Intervention: Culturally tailored skills‐based educational intervention with telephone follow‐up
Number of subjects: 552

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 552
Study: 29210627

Group type: EXPERIMENTAL
Intervention: Nevirapine extended release (NVP-XR) 400 mg once daily
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Nevirapine immediate release (NVP-IR) 200 mg twice daily
Number of subjects: 1011
Study: 26380444

Group type: EXPERIMENTAL
Intervention: Qianjin Kouchuang Jiawei Granule (QKJG), 20 g each time, twice per day.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Kouyanqing Granule (KG), 20 g each time, twice per day.
Number of subjects: 120

Group type: COMPARATOR
Intervention: QKJG vs KG at day 3 after treatment.
Number of subjects: 120

Group type: COMPARATOR
Intervention: QKJG vs KG at day 7 after treatment.
Number of subjects: 120

Group type: COMPARATOR
Intervention: QKJG vs KG at month 12 after treatment.
Number of subjects: 120
Study: 23589771

Group type: EXPERIMENTAL
Intervention: ACTION (n = 28)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (n = 23)
Number of subjects: 60
Study: 21525866

Group type: EXPERIMENTAL
Intervention: Prebiotic oligosaccharide mixture (15 or 30 g scGOS/lcFOS/pAOS daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 18652320

Group type: EXPERIMENTAL
Intervention: Catgut implantation at Shu- and Mu-acupoints of liver, spleen and kidney
Number of subjects: 132

Group type: COMPARATOR
Intervention: Oral administration of Estradiol Valerate 2 mg, qd for 20 days, followed by Medroxyprogesterone Acetate 4 mg, b.i.d for 10 days
Number of subjects: 132
Study: 16464714

Group type: EXPERIMENTAL
Intervention: PET rubidium-82 myocardial perfusion imaging
Number of subjects: 224

Group type: COMPARATOR
Intervention: SPECT technetium-99m sestamibi myocardial perfusion imaging
Number of subjects: 224
Study: 12753987

Group type: EXPERIMENTAL
Intervention: 3-ml lidocaine-adrenaline injection before tonsillectomy
Number of subjects: 52
Study: 10966140

Group type: EXPERIMENTAL
Intervention: REG at hand switch rates of 45 rpm (REG‐45)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: REG at hand switch rates of 60 rpm (REG‐60)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Peak REG scores
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity values of the REG test
Number of subjects: 146
Study: 9264559

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery at second-look laparotomy
Number of subjects: 153
Study: 1301468

Group type: EXPERIMENTAL
Intervention: Altruistic behavior condition
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Outcome expectation condition
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Altruistic behavior viewpoint condition
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Outcome expectation viewpoint
Number of subjects: 155

Group type: COMPARATOR
Intervention: Non-observational control
Number of subjects: 155
Study: 3551180

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (KABI fragment 2165) 1 X 2'500 anti-factor Xa IU
Number of subjects: 189

Group type: COMPARATOR
Intervention: Unfractionated heparin 2 X 5'000 IU
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (KABI fragment 2165) 1 X 7'500 anti-factor Xa IU
Number of subjects: 189
Study: 31584766

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 44
Study: 28399334

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction using video eyeglasses
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional behavior management techniques
Number of subjects: 48
Study: 27112531

Group type: EXPERIMENTAL
Intervention: Epoetin Hospira (100 U/kg, subcutaneously, 3 times per week for 28 days)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Epogen (100 U/kg, subcutaneously, 3 times per week for 28 days)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Number of subjects: 129

Group type: COMPARATOR
Intervention: Epogen
Number of subjects: 129
Study: 26176061

Group type: EXPERIMENTAL
Intervention: Abdominal drainage
Number of subjects: 200

Group type: COMPARATOR
Intervention: No abdominal drainage
Number of subjects: 200
Study: 22621180

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 12.0 U
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 7.5 U
Number of subjects: 60
Study: 20193834

Group type: EXPERIMENTAL
Intervention: OAC (warfarin-containing regimens)
Number of subjects: 24542

Group type: COMPARATOR
Intervention: No OAC (non-OAC regimens)
Number of subjects: 24542
Study: 17894654

Group type: EXPERIMENTAL
Intervention: Mitemcinal 10 mg bid
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mitemcinal 20 mg bid
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mitemcinal 30 mg bid
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mitemcinal 20 mg tid
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 15196109

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg kg(‐1) bolus followed by 2 microg kg(‐1) min(‐1) infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study: 12452304

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2, n=60)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Conservative treatment (group 1, n=11)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2) without cardiogenic shock
Number of subjects: 171

Group type: COMPARATOR
Intervention: Conservative treatment (group 1) without cardiogenic shock
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Conservative treatment (group 1)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (group 2) and conservative treatment (group 1) in cardiogenic shock
Number of subjects: 171
Study: 9817339

Group type: EXPERIMENTAL
Intervention: Surface neuromodulation via transcutaneous electrical nerve stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham transcutaneous electrical nerve stimulation
Number of subjects: 0
Study: 7711987

Group type: EXPERIMENTAL
Intervention: Zetir (10 mg cetirizine dihydrochloride)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Zyrtek (10 mg cetirizine dihydrochloride)
Number of subjects: 14
Study: 2570799

Group type: EXPERIMENTAL
Intervention: terfenadine, 60 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: chlorpheniramine maleate, 8 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 720103

Group type: EXPERIMENTAL
Intervention: Topical application of 0.05 ml of Finalgon Strong Ointment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Brisk rubbing for 20 sec (control ear)
Number of subjects: 51
Study: 31329148

Group type: EXPERIMENTAL
Intervention: 2-D Stochastic Configuration Networks (2DSCNs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-D Stochastic Configuration Networks (1DSCNs)
Number of subjects: 0
Study: 30694974

Group type: EXPERIMENTAL
Intervention: Combined histamine H1 and H2 receptor antagonists (Blockade)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 28637064

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.004 mg/kg IM)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (2.0 mL normal saline solution IM)
Number of subjects: 196
Study: 26089306

Group type: EXPERIMENTAL
Intervention: IPS-LITE
Number of subjects: 123

Group type: COMPARATOR
Intervention: IPS
Number of subjects: 123
Study: 23985175

Group type: EXPERIMENTAL
Intervention: Rural patients
Number of subjects: 972
Study: 20146595

Group type: EXPERIMENTAL
Intervention: Recollection of objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recollection of faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recollection of words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three stimulus materials (objects, words, faces)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Objects and faces (when stimulus categories were blocked)
Number of subjects: 0
Study: 19930724

Group type: EXPERIMENTAL
Intervention: 500,000 IU vitamin D3 (cholecalciferol) every autumn for five consecutive years
Number of subjects: 2317

Group type: COMPARATOR
Intervention: Placebo every autumn for five consecutive years
Number of subjects: 2317
Study: 15753411

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11846193

Group type: EXPERIMENTAL
Intervention: ABM/P-15
Number of subjects: 25
Study: 10075160

Group type: EXPERIMENTAL
Intervention: PENTA vaccine at 12 months
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: PENTA vaccine at 15 months
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: PENTA vaccine at 18 months
Number of subjects: 253
Study: 7669467

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg kg‐1 i.v., followed by 5 micrograms kg‐1 min‐1
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 2269712

Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchangers (HME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchangers (HME) after 12 hours of continuous use
Number of subjects: 0
Study: 6119244

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 31544379

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding at Ganshu (BL 18), Pishu (BL 20), Sanyinjiao (SP 6), once a week for 12 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Vitamin C (200 mg, 3 times a day) and Vitamin E (100 mg, once a day) for oral administration for 12 weeks
Number of subjects: 92
Study: 28408148

Group type: EXPERIMENTAL
Intervention: Brass wire ligature treatment with mandibular third molar germectomy (group A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Brass wire ligature treatment without mandibular third molar germectomy (group B)
Number of subjects: 14
Study: 26413816

Group type: EXPERIMENTAL
Intervention: Anti-C. trachomatis IgG3 seropositivity
Number of subjects: 1250
Study: 23419459

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA detrusor injections
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no OnabotulinumtoxinA injections)
Number of subjects: 10
Study: 21233462

Group type: EXPERIMENTAL
Intervention: FAME therapy (family-mediated exercise therapy) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine therapy with no formal input from family members (Control)
Number of subjects: 40
Study: 19436681

Group type: EXPERIMENTAL
Intervention: Losartan (25 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 17518883

Group type: EXPERIMENTAL
Intervention: Nurse short message service (SMS) intervention for six months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 51
Study: 15361495

Group type: EXPERIMENTAL
Intervention: Diet excluding all foods to which they had raised IgG antibodies
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham diet excluding the same number of foods but not those to which they had antibodies
Number of subjects: 150
Study: 11600749

Group type: EXPERIMENTAL
Intervention: Vegan diet free of gluten
Number of subjects: 66

Group type: COMPARATOR
Intervention: Non-vegan diet
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 10078794

Group type: EXPERIMENTAL
Intervention: Educational intervention package
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 236
Study: 7979622

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg four times a day)
Number of subjects: 43
Study: 2692093

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Six Minute Walk Test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rating of dyspnea following the walk test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CRQ dyspnea score
Number of subjects: 24
Study: 1095114

Group type: EXPERIMENTAL
Intervention: Fast neutrons
Number of subjects: 102

Group type: COMPARATOR
Intervention: X or gamma rays (photons)
Number of subjects: 102
Study: 31735700

Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (Li-ESWT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Li-ESWT
Number of subjects: 0
Study: 30543483

Group type: EXPERIMENTAL
Intervention: Fermented ginseng (FG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonfermented ginseng (NFG)
Number of subjects: 12
Study: 28608496

Group type: EXPERIMENTAL
Intervention: Intravenously pantoprazole 40 mg once daily
Number of subjects: 3350
Study: 26244837

Group type: COMPARATOR
Intervention: Physiologic saline (Group 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gentamicin solution (Group 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clindamycin solution (Group 3)
Number of subjects: 51
Study: 23280086

Group type: EXPERIMENTAL
Intervention: ALL‐2 regimen (cytarabine 3 g/m(2) daily for 5 days with mitoxantrone 80 mg/m(2))
Number of subjects: 164

Group type: COMPARATOR
Intervention: L‐20 regimen (standard 4‐drug induction)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ALL‐2 regimen
Number of subjects: 164

Group type: COMPARATOR
Intervention: L‐20 regimen
Number of subjects: 164